Don’t Trade in the Dark—Get Your Pre-Market Report Every Day.Join Now
Healthcare | Mid Cap
Health Score : 7.10Laurus Labs Ltd. presents a mixed but generally positive financial profile. The company's greatest strengths are its exceptional profitability, outstanding growth prospects, and rock-solid financial structure. It has very low levels of debt, meaning it is not burdened by large interest payments and has a stable long-term foundation. Projections indicate a massive rebound in revenue and profits, suggesting that a recent downturn was a temporary event. However, the company faces significant challenges in its operational efficiency. It takes a very long time to sell its products and collect payments from customers, which ties up cash and can strain day-to-day finances. This is also reflected in its tight liquidity position, with limited cash immediately available to cover short-term expenses. Overall, it's a highly profitable and fast-growing company with a strong balance sheet, but its operational and cash management processes are areas of weakness.
Health Score : 7.10Laurus Labs Ltd. presents a mixed but generally positive financial profile. The company's greatest strengths are its exceptional profitability, outstanding growth prospects, and rock-solid financial structure. It has very low levels of debt, meaning it is not burdened by large interest payments and has a stable long-term foundation. Projections indicate a massive rebound in revenue and profits, suggesting that a recent downturn was a temporary event. However, the company faces significant challenges in its operational efficiency. It takes a very long time to sell its products and collect payments from customers, which ties up cash and can strain day-to-day finances. This is also reflected in its tight liquidity position, with limited cash immediately available to cover short-term expenses. Overall, it's a highly profitable and fast-growing company with a strong balance sheet, but its operational and cash management processes are areas of weakness.
Overall Valuation Score
Markets Depth NSE
Buy Orders
Bid
Quantity
Orders
No buy depth
Total
0
0
Sell Orders
Ask
Quantity
Orders
No sell depth
Total
0
0
Markets Today NSE
High
0.00
Low
0.00
Open
0.00
Close
0.00
Prev Close
0.00
Avg Price
0.00
Volume
0
Last Traded Quantity
0
Last Traded Time
N/A
Price Movement Indicator
Today's Low: 0.00
Today's High: 0.00
P/E RATIO (TTM)
135.69
Industry Median
30.91
Mid Cap Median
44.19
P/E RATIO
113.10
P/B RATIO
18.96
Industry Median
3.69
Mid Cap Median
6.64
P/S RATIO
14.35
Industry Median
3.74
Mid Cap Median
6.84
Others
PEG RATIO
0.00
EV/EBITDA RATIO
53.68
The Calculations Shown Above Are Based on the Last Traded Price (LTP) of ₹1861.6 as on Sep 1, 2026.
Growth Score : 10.00The company's growth outlook is exceptionally strong. Despite a significant contraction in the most recent fiscal year, the weighted average and forward-looking estimates project a powerful and rapid recovery. Strong growth is anticipated across revenue, operating profit, and net income. This suggests that the market and analysts view the recent challenges as temporary and expect the company to return to a high-growth trajectory, underpinned by consistent expansion of its asset base to support future business.
Revenue Growth RateExcellentOperating Profit Growth RateExcellentEarnings Per Share (EPS) GrowthExcellentAsset Growth RateExcellentNet Income Growth RateExcellent| Growth Ratios | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Revenue Growth Rate | 2.53 | 22.39 | -16.55 | 10.18 | 22.67 |
| Operating Profit Growth Rate | -8.25 | 11.8 | -51.07 | 35.43 | 68.53 |
| Earnings Per Share (EPS) Growth | -15.98 | -4.74 | -79.69 | 122.82 | 147.89 |
| Asset Growth Rate | 21.16 | 9.93 | 9.49 | 11.32 | 12.59 |
| Net Income Growth Rate | -15.45 | -4.69 | -79.57 | 120.99 | 148.6 |
Revenue Growth Rate
Operating Profit Growth Rate
Earnings Per Share (EPS) Growth
Asset Growth Rate
Net Income Growth Rate
Peer Comparison empowers investors to evaluate a company against its industry peers using key financial metrics like P/E ratio, EPS, and profit margins. It helps identify whether a company is overvalued, undervalued, or performing in line with competitors. Investors can use this data to spot opportunities, assess risks, and make informed decisions. This contextual view adds depth beyond standalone company analysis.
| NO | Company Name | Health Score | P/E Ratio | Valuation | OPM | EPS | Latest Profit & Loss |
|---|---|---|---|---|---|---|---|
| 1 | Abbott India Ltd | 8.68 | 35.78 | Neutral | 1892.00 | 730.39 | 1552.00 |
| 2 | Glaxosmithkline Pharmaceuticals Ltd | 8.38 | 49.00 | Neutral | 1309.00 | 59.73 | 1036.00 |
| 3 | J B Chemicals & Pharmaceuticals Ltd | 8.14 | 54.51 | Overvalued | 1107.00 | 41.98 | 709.00 |
| 4 | Alkem Laboratories Ltd | 8.08 | 27.53 | Neutral | 3005.00 | 182.76 | 2351.00 |
| 5 | Gland Pharma Ltd | 7.91 | 46.11 | Overvalued | 1630.00 | 78.78 | 1027.00 |
| 6 | Ajanta Pharma Ltd | 7.72 | 41.47 | Neutral | 1395.00 | 75.78 | 1056.00 |
| 7 | Emcure Pharmaceuticals Ltd | 7.40 | 37.86 | Neutral | 1865.00 | 38.64 | 941.00 |
| 8 | Syngene International Ltd | 7.16 | 51.15 | Neutral | 918.00 | 7.55 | 317.00 |
| 9 | Laurus Labs Ltd | 7.10 | 113.10 | Neutral | 1778.00 | 13.71 | 890.00 |
| 10 | Glenmark Pharmaceuticals Ltd | 6.36 | 51.19 | Neutral | 4572.00 | -7.12 | 1362.00 |
| 11 | Ipca Laboratories Ltd | 6.33 | 44.19 | Overvalued | 1979.00 | 44.64 | 1184.00 |
| 12 | Piramal Pharma Ltd | 5.83 | -87.02 | Neutral | 922.00 | 5.26 | -326.00 |
| 13 | Pfizer Ltd | 3.45 | 46.48 | Neutral | -82.00 | 157.92 | 300.00 |
0 Credits RemainingUnlock Deep Technical Insights in Seconds Only with Dhanarthi AI
Overall Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
Market Sentiment
Analysis Driven By 26 Technical Indicators From The 1 Hour Timeframe
Trend Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bearish
Momentum Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bearish
Volatility Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bullish
Volume Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
Analyzing moving average trends and crossovers. Green/Red badges indicate if the current condition passes or fails.
Comparing stock price performance (normalized) against benchmark indices over time.
Recent daily trading volume represented as a bar chart, alongside historical averages.
Current closing price relative to the 52-week highest and lowest prices.
Concall Report⬤5th May 26
Q4 FY26 Earnings Conference Call
BULLISH SENTIMENT
Quarterly Report⬤30th Apr 26
Audited Consolidated Financial Results for the Year Ended March 31, 2026
BULLISH SENTIMENT
Quarterly Report⬤23rd Jan 26
Quarterly Financial Results Q3 FY 2025-26
BULLISH SENTIMENT
Laurus Labs Ltd. is a research and development-driven Indian pharmaceutical company. It specializes in manufacturing active pharmaceutical ingredients (APIs) across various therapeutic areas, finished dosage forms (FDFs), and offers contract development and manufacturing organization (CDMO) services. The company has a strong presence in anti-retroviral, oncology, and other high-growth segments, leveraging its integrated capabilities from API to formulation.
P/E Ratio (TTM): Price to Earnings ratio shows how much an investor pays for every rupee of the company's earnings. Laurus Labs Ltd's P/E ratio (TTM) is 135.69, compared to the industry median of 30.91 and large cap median of 44.19.
P/B Ratio: Price to Book ratio compares a company's market price to its book value per share. Laurus Labs Ltd's P/B ratio is 18.96, compared to the industry median of 3.69 and large cap median of 6.64.
P/S Ratio: Price to Sales ratio compares a company's market value to its total revenue. Laurus Labs Ltd's P/S ratio is 14.35, compared to the industry median of 3.74 and large cap median of 6.84.
PEG Ratio: PEG ratio adjusts the P/E ratio for expected earnings growth. Laurus Labs Ltd's PEG ratio is 1.75.
EV/EBITDA Ratio: This ratio compares a company's enterprise value to its earnings before interest, tax, depreciation, and amortization. Laurus Labs Ltd's EV/EBITDA ratio is 53.68.
Return on Equity (ROE): ROE measures how much profit a company generates from shareholders' invested capital. Laurus Labs Ltd's ROE is 16.79%.
Return on Assets (ROA): ROA measures how efficiently a company converts its assets into net profit. Laurus Labs Ltd's ROA is 16.92%.
Return on Capital Employed (ROCE): ROCE measures how efficiently a company generates profit from all the capital it employs. Laurus Labs Ltd's ROCE is 18%.
Operating Margin: Operating margin shows what percentage of revenue remains after covering operating expenses. Laurus Labs Ltd's operating margin is 26.10%.
Net Margin: Net margin shows what percentage of revenue converts into final net profit. Laurus Labs Ltd's net margin is 13.06%.
Current Ratio: The current ratio measures a company's ability to pay short-term liabilities using short-term assets. Laurus Labs Ltd's current ratio is 1.13.
Debt to Equity Ratio: This ratio shows the proportion of debt a company uses relative to shareholders' equity. Laurus Labs Ltd's debt-to-equity ratio is 0.14.
Interest Coverage Ratio: This ratio shows how easily a company can pay interest on its outstanding debt from its operating earnings. Laurus Labs Ltd's interest coverage ratio is 7.91.
Dividend Per Share (DPS): DPS shows the total dividend paid per share in the latest financial year. Laurus Labs Ltd's DPS is ₹1.15.
Earnings Per Share (EPS): EPS shows how much profit is allocated to each outstanding share. Laurus Labs Ltd's EPS is 147.89.
(Source line: "Ratios as of 25 Sept 2026, based on last traded price of ₹1861.60. Data sourced from BSE/NSE Exchange Filings & Public Terminal Data.")
Founded: 2005
Headquarters: Hyderabad, Telangana
Core Offerings: Active Pharmaceutical Ingredients (APIs), Finished Dosage Forms (FDFs), Contract Development and Manufacturing Organization (CDMO), Bio-Tech
Stock Listing: NSE (LAURUSLABS), BSE (540222)
Promoter: Dr. Satyanarayana Chava
Founded in 2005 by Dr. Satyanarayana Chava, Laurus Labs began as a pure-play API manufacturer, quickly establishing leadership in anti-retroviral (ARV) APIs. The company diversified into custom synthesis for innovator companies in 2007, and later expanded into finished dosage forms (FDFs) in 2013. It successfully completed its Initial Public Offering (IPO) in 2016 and has since grown to become an integrated pharmaceutical player with capabilities spanning API, FDF, CDMO, and biotechnology, serving global markets.
| Segment Name | Revenue % | EBITDA |
|---|---|---|
| API (Active Pharmaceutical Ingredients) | 46% | Contributes significantly to overall EBITDA |
| Formulations | 45% | Growing segment, contributes to overall EBITDA |
| CDMO - Synthesis (Contract Development and Manufacturing Organization) | 8% | Contributes to overall EBITDA |
| Bio (Biotechnology) | 1% | Emerging segment, contributing to future growth |
API (Active Pharmaceutical Ingredients): Focuses on complex APIs for therapeutic areas such as Anti-retroviral, Oncology, Cardiovascular, Anti-diabetic, and other high-growth areas, serving both generic and innovator pharmaceutical companies globally.
Formulations: Manufactures and sells Finished Dosage Forms (FDFs) in various therapeutic categories, including anti-retroviral, cardiology, oncology, and diabetology. It caters to both regulated and emerging markets.
CDMO - Synthesis: Provides contract development and manufacturing services for innovator companies, offering custom synthesis, process development, and manufacturing of advanced intermediates and APIs.
Bio: Engaged in the development and manufacturing of recombinant products, including enzymes and biologics, for pharmaceutical and industrial applications.
Dr. Satyanarayana Chava: Founder, CEO & Whole-time Director. A visionary leader with over 30 years of experience in the pharmaceutical industry, he founded Laurus Labs and has been instrumental in its growth and strategic direction.
Laurus Synthesis Private Limited
Laurus Bio Pvt Ltd
Laurus Generics Inc. (USA)
Laurus Generics GmbH (Germany)
Notable recent corporate actions include a bonus issue in 2020 (1:2) and a stock split in 2021 (1:5).
The Laurus Labs Ltd share price today is ₹1861.60 on NSE (LAURUSLABS), as of 25 Sept 2026.
As of 25 Sept 2026, Laurus Labs Ltd share price is ₹1861.60, with previous close ₹1861.60. Today's range is ₹1861.60 to ₹1861.60. The 52-week range is ₹917.95 to ₹2055.30.
As of today, Laurus Labs Ltd's market cap is ₹97,771.23 crore (Large Cap).
Laurus Labs Ltd's current P/E ratio is 135.69, compared to the PHARMACEUTICALS & BIOTECHNOLOGY sector average of 38.
Laurus Labs Ltd's current P/B ratio is 18.96.
Laurus Labs Ltd's current dividend yield is 0.06%. Last dividend of ₹0.60 per share was declared on 10-May-2024.
Laurus Labs Ltd's EPS (TTM) is ₹147.89.
Laurus Labs Ltd. is a research and development-driven Indian pharmaceutical company. It specializes in manufacturing active pharmaceutical ingredients (APIs) across various therapeutic areas, finished dosage forms (FDFs), and offers contract development and manufacturing organization (CDMO) services. The company has a strong presence in anti-retroviral, oncology, and other high-growth segments, leveraging its integrated capabilities from API to formulation.
Laurus Labs Ltd is promoted by Dr. Satyanarayana Chava, holding 27.49% as of 25 Sept 2026.
Laurus Labs Ltd is listed on NSE (LAURUSLABS) and BSE (540222). Its next quarterly results are expected on August 2024.
Adjusted Earnings Per Share (Adjusted EPS)
